Dyne Therapeutics announces leadership announcements

Dyne Therapeutics announced leadership appointments. Doug Kerr has been appointed Chief Medical Officer succeeding Wildon Farwell, who is stepping down from his role and will remain at Dyne full-time through the end of 2024 to assist in the continued execution of the company’s clinical plans. In addition, Johanna Friedl-Naderer is joining Dyne as Chief Commercial Officer and Lucia Celona has been appointed Chief Human Resources Officer. Doug Kerr brings more than 25 years of expertise in early-and late-stage clinical development. For the last year, Kerr was a venture partner at Atlas Venture. From 2017 to 2023, he was member of Generation Bio, joining initially as the head of research and development and most recently serving as its CMO. Johanna Friedl-Naderer, CCO, brings more than two decades of biopharmaceutical industry experience in global commercialization including product launches in rare disease. Most recently Friedl-Naderer served as COO of Vir Biotechnology in the field of infectious disease. As president Europe, Canada & Partner Markets for Biogen, she led her team to launch multiple specialty and rare disease products. Lucia Celona, CHRO, brings more than 30 years of experience in organizational design and effectiveness. At Biogen, she served as the vice president of HR for pharmaceutical operations & technology, where she was the lead HR business partner responsible for the strategic partnership with senior leaders and driving HR strategies that enabled commercial success. Following her tenure at Biogen, she became the chief HR and communications officer at Bioverativ. Additionally, she oversaw the HR and corporate communications functions at Apellis. In addition, Susanna High, COO, and Jonathan McNeill, Chief Business Officer, have decided to step down from their roles to pursue other opportunities.